Cyclic Boronates Inhibit All Classes of β-Lactamases by Cahill, Samuel T et al.
                          Cahill, S. T., Cain, R., Wang, D. Y., Lohans, C. T., Wareham, D. W., Oswin,
H. P., ... Brem, J. (2017). Cyclic Boronates Inhibit All Classes of -
Lactamases. Antimicrobial Agents and Chemotherapy, 61(4), [e02260-16].
DOI: 10.1128/AAC.02260-16
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1128/AAC.02260-16
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via ASM at
http://aac.asm.org/content/61/4/e02260-16. Please refer to any applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published




Cyclic Boronates Inhibit All Classes of -Lactamase 1 
Samuel T. Cahilla, Ricky Caind, David Y. Wanga, Christopher T. Lohansa, David W. 2 
Warehamb, Henry P. Oswinc, Jabril Mohammedc, James Spencerc, Colin W. G. Fishwickd, 3 
Michael A. McDonougha, Christopher J. Schofielda† & Jürgen Brema† 4 
aChemistry Research Laboratory, University of Oxford, Oxford, UK 5 
bQueen Mary University of London, London, UK 6 
cSchool of Cellular and Molecular Medicine, University of Bristol, Bristol, UK 7 
dSchool Of Chemistry, University of Leeds, Leeds, UK 8 
†Corresponding author (Jürgen Brem email: jurgen.brem@chem.ox.ac.uk, Christopher 9 
















Supplemental Material 24 
Supplemental Methods 
Supplemental Tables     
Page   3  
Pages  4 - 7 
Supplemental Figures Pages  8 - 15 
Supplemental Disc Diffusion Test Images 
References 





















Supplemental Methods 42 
 43 
Steady-state kinetics 44 
Steady-state kinetics studies used a Pherastar FS microplate reader with UV-STAR® 96-well, 45 
half area, µclear® plates (Greiner Bio-One) for nitrocefin experiments and 96-well, half area, 46 
black, µclear® plates (Greiner Bio-One) for FC5 (1). Buffers employed were 100 mM 47 
phosphate buffer pH 7.5, 0.01% (v/v) Triton X-100 for TEM-1, CTX-M-15 and AmpC, 100 mM 48 
phosphate buffer pH 7.5, 50 mM sodium bicarbonate, 0.01% Triton X-100 for OXA-23 and 49 
OXA-48 and 50 mM HEPES pH 7.5, 1 M ZnSO4, 0.01% Triton X-100 and 50 mM MES pH 6.5, 50 
1 M ZnSO4, 0.01% Triton X-100 for MBL assays. Reaction progress was monitored at 298 K 51 
by following changes in absorbance at 485 nm for nitrocefin and changes in fluorescence 52 
intensity (ex = 380 nm, em = 480 nm) for FC5 (1). Suitable enzyme concentrations for 53 
kinetic analysis were determined by monitoring changes in absorbance/fluorescence for 54 
enzyme concentrations between 20 nM and 20 pM. The determined values are provided in 55 
Table S2. Kinetic constants were determined using the initial rate of hydrolysis with the 56 
reaction initiated through the addition of enzyme to pre-prepared substrate concentrations. 57 
Substrate concentrations ranged between 400 M and 0.4 M. The Michaelis-Menten 58 
equation was fitted to data by non-linear regression using GraphPad Prism software to 59 
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Table S1. Sequences of primers used in the cloning of CTX-M-15, Pseudomonas aeruginosa 67 

















Enzyme Substrate [E] (pM) kcat (s
-1) Km (M) kcat/Km (M s
-1) 
CTX-M-15 Nitrocefin* 100 1000 ± 120 80 ± 14 13 
 
FC5 50 1100 ± 100 170 ± 20 6.5 
AmpC Nitrocefin 250 540 ± 40 100 ± 20 5.4 
 
FC5 500 500 ± 160 600 ± 220 0.83 
OXA-23 Nitrocefin 2000 2800 ± 200 50 ± 9 56 
 
FC5 1000 38 ± 7 500 ± 130 0.076 
OXA-48 Nitrocefin 2000 4800 ± 200 62 ± 8  77 
 FC5 1000 28 ± 2 420 ± 50 0.067 
 83 
Table S2. Kinetic constants for the -lactamase-catalysed hydrolysis of FC5 (1) and, for 84 
comparison the more commonly used reporter substrate nitrocefin (3). Data were fitted 85 
using GraphPad Prism 5 (2). *Indicates that substrate-based inhibition was observed 86 


















Synergy When Combined with (2): Fixed 2:1 µg Ratio 
Isolate β-Lactamases Produced CAR PRL TZP KF C/T TEM MEL CTX CAZ SAM CPT FEP AZT IPM CAZ/AVI AUG ERT FOX MEM 
E.coli (EC107) ST 131 CTX-M-15 (A), OXA-1 (D) N Y N N N Y N Y Y N Y Y Y N N N N Y N 
E.coli (EC114) ST 131 TEM-1 (A), CTX-M-15 (A), OXA-1 (D) N Y N N N Y N Y Y N Y Y Y N N N N Y N 
E.coli (EC86) CTX-M-15 (A), CMY-4 (C), OXA-181 (D) N N Y N Y N N N N N N N Y N N N N N N 
E.coli (EC113) ST 131 CTX-M-27 (A) N Y N Y N N N Y Y N Y Y Y N N Y N N N 
K. pneumoniae (KP15) TEM-1 (A), SHV-11 (A), KPC-2 (A) N Y Y N Y Y Y Y N N N Y Y Y N N Y Y Y 
K. pneumoniae (KP41) 
TEM-1 (A), SHV-1 (A), -5 (A), -11 (A), 
CTX-M-15 (A), OXA-232 (D) 
N N N N Y N N N N N N N N N N N N N N 
K. pneumoniae (KP58) SHV-11 (A), VIM-4 (B) N Y Y N Y Y Y Y N N N Y Y Y N N Y N Y 
P. stuartii (PS71) TEM-1 (A), SHV-5 (A), VEB-1 (A), VIM-1 (B) N Y N N Y N N Y N N N Y Y N N N N N N 
P. aeruginosa (PA12) ST 111 VIM-2 (B) N Y Y N Y N N N N N N N Y N N N N N N 
A. baumannii (AB14) OXA-51 (D), OXA-23 (D) N N N N N N N N N N N Y N N N N N N N 
 102 
Supplementary Table S3: Synergy in Disc Diffusion Assays between 2 and β-lactams: CAR: Carbenacillin; PRL: Piperacillin; TZP: 103 
Piperacillin/Tazobactam; KF: Cephalothin; C/T: Ceftolozane/Tazobactam; TEM: Temocillin; MEL: Mecillinam; CTX: Cefotaxime; CAZ: 104 
Ceftazidime; SAM: Ampicillin/Sulbactam; CPT: Ceftaroline; FEP: Cefepime; AZT: Aztreonam: IPM: Imipenem; CAZ/AVI: 105 






Data Set CTX-M-15:1 Complex 
Data Collection  
   Source Rotating Copper Anode 
   Resolution Range (Å) 21.68 – 1.95 (2.02 – 1.95)a 
   Space Group P 2 21 21 
Unit Cell Parameters  
   a, b, c (Å) 43.5, 76.1, 149.4 
,, 90.0, 90.0, 90.0 
   Unique Reflections 36639 (3565)a 
   Completeness (%) 99.07 (99.56)a 
   Redundancy 5.3 
   Rmerge 0.12 (0.10)
a 
   <I/(I)> 5.3 (1.6)
a 
Refinement  
   Rwork/Rfree 0.2003/0.2341 
RMSD  
   Bonds (Å) 0.003 
   Angles (°) 0.61 
   Average B-factor for protein atoms (Å2) 19.31 
Ramachandran Plot  
   Most Favoured Geometry (%) 98.0 
   Additionally Allowed (%) 1.1 
   Outliers (%) 0.4 
 110 
Table S4: Crystallographic data and refinement statistics for the CTX-M-15:1 complex. 111 




















Figure S2: Hydrolysis of nitrocefin catalysed by CTX-M-15, AmpC, OXA-23 and OXA-48. The 130 
initial rate of reaction is plotted against substrate concentration. The concentrations of 131 
the enzymes employed in the work are indicated. Solid lines indicate the Michaelis-132 





Figure S3: Hydrolysis of FC5 catalysed by CTX-M-15, AmpC, OXA-23 and OXA-48. The initial 136 
rate of reaction is plotted against substrate concentration. The concentrations of the 137 
enzymes employed in the work are indicated. Solid lines indicate the Michaelis-Menten 138 



















Figure S4: IC50 curves for serine--lactamase inhibition time courses. Residual activities 156 
were calculated from the initial rate of FC5 hydrolysis after incubation of the enzyme with 157 







Figure S5: IC50 curves for metallo--lactamase inhibition time courses. Residual activities 163 
were calculated from the initial rate of FC5 hydrolysis after incubation of the enzyme with 164 













Figure S6. Impact of boronate 1 on carbamylation of the OXA-10 active site lysine residue. 176 
13C NMR reveals a change in the environment of the carbamylated lysine upon binding of 177 
1, with a corresponding shift of 6 ppm. Notably, the carbamylation state of the lysine is 178 



















Figure S7: View from a crystal structure of the CTX-M-15 active site with bound cyclic 196 
boronate 1, PDB accession code: 5T66.  Representative electron density for 2 is shown (3.0 197 











Figure S8. A. The conformation of the monocyclic boronate inhibitor RPX-7009 when 207 
bound to CTX-M-15 (blue, PDB accession code: 4XUZ (4)) and an overlay with that of 1 as 208 
observed in the CTX-M-15:1 structure (green, PDB Accession Code: 5T66). B. The 209 
conformation of the inhibitor BJH when bound to TEM-1 (grey, PDB Accession Code: 1ERQ 210 
(5)) and an overlay with that of 1 as observed in the CTX-M-15:1 structure (green, PDB 211 
Accession Code: 5T66). Note that BJH has the potential to form a bicyclic scaffold in the 212 
same manner as 2 (via formation of a bond between its phenolic oxygen and the boron, 213 
BJH (Cyclic)), but the boronate is interpreted as acyclic in the deposited complex structure. 214 





Figure S9: The diversity among conformations of -lactamase:-lactam intermediate and 218 
product complexes. Overlays of OXA-10:6-(1-hydroxy-1-methylethyl penicillanic acid( 219 
blue), OXA-13:meropenem (green), NDM-1:benzylpenicillin (yellow), and NDM-220 







    Supplemental Disc Diﬀusion Test Images: Plate Plan  
 
CAR: Carbenacillin   PRL: Piperacillin    TZP: Piperacillin/Tazobactam   KF: Cephalothin 
 
           
     C/T: Ce olazone/Tazobactam 
 
 






CPT: Ce aroline       FEP: Ceﬁpime         AZT: Aztreonam                       IPM: Imipenem 
 
            
    CAZ/AVI: Ce azidime/Avibactam 
 
 
AUG: Amoxicillin/Clavulanate       ERT: Ertapenem    FOX: Cefoxi n     MEM: Meropenem 
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Escherichia coli EC107: CTX-M-15 and OXA-1 
Activity enhanced by 2  β-lactam (µg) 
                                 + 2 2:1 ratio  
Synergy with Avibactam 
Synergy with Clavulanate 
Synergy with Tazobactam Synergy with Tazobactam / 2  
Synergy with Avibactam / 2  
 Synergy with Clavulanate / 2  
Synergy with Sulbactam Synergy with Sulbactam / 2  
Escherichia coli EC114: TEM-1, CTX-M-15 and OXA-1 
Activity enhanced by 2  β-lactam (µg) 
                                 + 2 2:1 ratio  
Synergy with Avibactam 
Synergy with Clavulanate 
Synergy with Tazobactam Synergy with Tazobactam / 2  
Synergy with Avibactam / 2  
 Synergy with Clavulanate / 2  
Synergy with Sulbactam Synergy with Sulbactam / 2  
Escherichia coli EC86: CTX-M-15,CMY-4 and OXA-181 
Activity enhanced by 2  β-lactam (µg) 
                                 + 2 2:1 ratio  
Synergy with Avibactam 
Synergy with Clavulanate 
Synergy with Tazobactam Synergy with Tazobactam / 2  
Synergy with Avibactam / 2  
 Synergy with Clavulanate / 2  
Synergy with Sulbactam Synergy with Sulbactam / 2  
Escherichia coli EC113: CTX-M-27 
Activity enhanced by 2  β-lactam (µg) 
                                 + 2 2:1 ratio  
Synergy with Avibactam 
Synergy with Clavulanate 
Synergy with Tazobactam Synergy with Tazobactam / 2  
Synergy with Avibactam / 2  
 Synergy with Clavulanate / 2  
Synergy with Sulbactam Synergy with Sulbactam / 2  
Klebsiella pneumoniae KP15: TEM-1, SHV-11, KPC-2 
Activity enhanced by 2  β-lactam (µg) 
                                 + 2 2:1 ratio  
Synergy with Avibactam 
Synergy with Clavulanate 
Synergy with Tazobactam Synergy with Tazobactam / 2  
Synergy with Avibactam / 2  
 Synergy with Clavulanate / 2  
Synergy with Sulbactam Synergy with Sulbactam / 2  
Klebsiella pneumoniae KP41:TEM-1, SHV-1,5,11, CTX-M-15, OXA-232 
Activity enhanced by 2  β-lactam (µg) 
                                 + 2 2:1 ratio  
Synergy with Avibactam 
Synergy with Clavulanate 
Synergy with Tazobactam Synergy with Tazobactam / 2  
Synergy with Avibactam / 2  
 Synergy with Clavulanate / 2  
Synergy with Sulbactam Synergy with Sulbactam / 2  
Klebsiella pneumoniae KP58: SHV-11, VIM-4 
Activity enhanced by 2  β-lactam (µg) 
                                 + 2 2:1 ratio  
Synergy with Avibactam 
Synergy with Clavulanate 
Synergy with Tazobactam Synergy with Tazobactam / 2  
Synergy with Avibactam / 2  
 Synergy with Clavulanate / 2  
Synergy with Sulbactam Synergy with Sulbactam / 2  
Providencia stuartii PS71: TEM-1, SHV-5, VEB-1, VIM-1 
Activity enhanced by 2  β-lactam (µg) 
                                 + 2 2:1 ratio  
Synergy with Avibactam 
Synergy with Clavulanate 
Synergy with Tazobactam Synergy with Tazobactam / 2  
Synergy with Avibactam / 2  
 Synergy with Clavulanate / 2  
Synergy with Sulbactam Synergy with Sulbactam / 2  
Pseudomonas aeruginosa PA12: VIM-2 
Activity enhanced by 2  β-lactam (µg) 
                                 + 2 2:1 ratio  
Synergy with Avibactam 
Synergy with Clavulanate 
Synergy with Tazobactam Synergy with Tazobactam / 2  
Synergy with Avibactam / 2  
 Synergy with Clavulanate / 2  
Synergy with Sulbactam Synergy with Sulbactam / 2  
Acinetobacter baumannii AB14: OXA-51, OXA-23 
Activity enhanced by 2  β-lactam (µg) 
                                 + 2 2:1 ratio  
Synergy with Avibactam 
Synergy with Clavulanate 
Synergy with Tazobactam Synergy with Tazobactam / 2  
Synergy with Avibactam / 2  
 Synergy with Clavulanate / 2  
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